Atacicept met its Phase 3 proteinuria reduction endpoint, supporting optimism for Vera's accelerated FDA approval filing ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

While Vanrafia may out pressure on new patient starts, the firm believes Filspari’s launch should continue upward due to the drug’s differentia SAN DIEGO, March 31, 2025--Travere's late ...

Atacicept is an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor.